A B S T R A C T Terminal deoxynucleotidyl transferase was purified to homogeneity from the blasts of eight patients with leukemia and compared with purified transferase from normal human and calf thymus. In two cases phenylmethanesulfonylfluoride was added during purification to reduce proteolysis. Comparative kinetic analyses of the purified enzymes indicated no differences in catalytic properties. There was substantial variation in the molecular structure of terminal transferase on denaturing polyacrylamide gels: (a) a protein that migrated as a single polypeptide with Mr = 62,000 was isolated from two patients with acute lymphoblastic leukemia and from cells; (b) a protein that migrated as a single polypeptide with Mr= 42,500 was isolated from two patients with acute lymphoblastic leukemia; (c) a protein that migrated as a single polypeptide with Mr = 42,500 was isolated from two patients with chronic myelogenous leukemia in blast crisis; (d) a protein that migrated as two nonidentical subunits of Mr = 27,000 and 10,000, respectively, was isolated from two additional patients with chronic myelogenous leukemia in blast crisis. The subunit structure ofd is characteristic of the homogeneous enzymes purified from human and calf thymus. Neutralizing and precipitating antibodies to terminal transferase from human lymphoblasts and calf thymus have been produced in rabbits and goats. Antisera directed INTRODUCTION Terminal deoxyribonucleotidyl transferase (terminal transferase, EC, 2.7.7.31)' is a DNA-polymerizing enzyme, which is widely used as a marker of neoplastic cells in certain human diseases (1) (2) (3) (4) . While an in vivo function has not yet been established for terminal transferase, a role in immunological programming has been suggested as a result of its location in mammalian thymus and bone marrow (5, 6) . A cytoplasmic location of thymic terminal transferase was established by subcellular fractionation (7) and by immunofluorescence detection of the enzyme in small thymocytes from adult animals (8) . On the other hand, terminal transferase in bone marrow cells, in immature thymocytes (9) , and in leukemic lymphoblasts (10) is present in the nucleus, as demonstrated by immunofluorescence. As a consequence, it has been suggested that terminal transferase in lymphoid tissue undergoes posttranslational cleavage and may form molecules that are enzy-matically active in vitro, but not biologically active in vivo (9) . Recently, we have reported a high molecular weight form of terminal transferase in blasts of a patient with acute lymphoblastic leukemia (ALL) (11) . The structural characteristics of this high molecular weight enzyme are different from the enzyme purified to homogeneity from calf thymus (12) . The differences between human lymphoblasts and calf thymus in subcellular location and structure of terminal transferase stimulated us to examine whether these differences represent a species or tissue variation or are related to the type of leukemia. We have purified and characterized terminal transferase from normal human thymus and from leukemic cells of patients with ALL and chronic myelogenous leukemia in blast crisis.
METHODS
Chemicals. Radioactive deoxynucleoside 5'-triphosphates were obtained from New England Nuclear, Boston, Mass. All nonradioactive nucleosides and nucleotides were purchased from Sigma Chemical Co. (St. Louis, Mo.), and were further purified (13) . Phenylmethanesulfonylfluoride (PMSF) was a product of Sigma Chemical Co. Oligo-(dT)cellulose ( Enzyme assays. The assay of human terminal transferase has been described (14 The reactions were incubated at 35°C for varying time periods, and terminated by application of 25-,ul aliquots onto GF/C glass fiber papers as described (15) . 1 U of enzyme activity is defined as 1 nmol of radioactive deoxynucleotide incorporated per hour, and specific activity is expressed as units of activity per milligram of protein.
Source ofleukemic cells. Human leukemic blasts were collected from patients undergoing therapeutic leukapheresis (16) . This procedure normally yields between 200 and 1,000 g of cells per patient. The lymphoblasts were purified by dextran sedimentation (2) . MOLT-4 is a terminal transferase containing lymphoblastoid cell line originally established from a patient with T-marked acute lymphoblastic leukemia (17) . At the time of enzyme purification, our line of MOLT-4 was no longer T marked. Variation in the surface markers of has been noted by numerous investigators. In one case, a spleen was obtained from a patient with ALL in relapse who required splenectomy. The material was immediately frozen and stored at -70°C.
Purification of terminal transferase from human blasts. Preparations ofterminal transferase from leukemic blasts were purified using the procedure summarized in Table I . In two preparations, the protease inhibitor, PMSF, was added in the extraction buffer at a concentration of 1 mM. A suspension of packed lymphoblasts (up to 2 kg of cells) was diluted with 3 vol of extraction buffer (0.25 M potassium phosphate, pH 7.2, containing 1 mM 2-mercaptoethanol) and mixed for 1 h at 40C. Our best results for extraction were obtained by passing the semithawed tissue through a chilled meat grinder before addition of the extraction buffer. The suspension was centrifuged at 10,000 g for 1 h at 4°C to yield the crude extract supernate (fraction I).
Fraction I (supernate) was diluted with 3 vol of 1 mM 2-mercaptoethanol and added to a carboy containing 2 liters of phosphocellulose slurry, equilibrated with 50 mM potassium phosphate, pH 7.2, 1 mM 2-mercaptoethanol (buffer A), per kilogram of tissue. The mixture was stirred for 2 h at 4°C, and the supernatant decanted after settling of the phosphocellulose. The gel was washed with equilibration buffer, and finally with 75 mM potassium phosphate, pH 7.2, containing 1 mM 2-mercaptoethanol. To facilitate elution of the bound terminal transferase, the phosphocellulose was poured into a glass column (10- (Table II) .
Fraction I was diluted with 4 vol of 1 mM 2-mercaptoethanol and 0.1 mM MgCl2, and applied to a column of oligo(dT)-cellulose (2.5 x 5.0 cm) equilibrated with buffer A. After a wash with 100 ml of buffer A, terminal transferase activity was eluted with a linear gradient (300 ml) from 0 to 1.2 M potassium chloride (in buffer A). Fractions containing terminal transferase activity were pooled and concentrated by ultrafiltration to yield fraction II.
Fraction II was diluted with 5 vol of 1 mM 2-mercaptoethanol containing 0.1 mM MgCl2, and applied to a column (1.2 x 5.5 cm) ofoligo(dT)6-15 (dA)0ol00 cellulose. This column material was prepared in our laboratory by polymerization of dATP to an average chain length of 50-100 residues onto oligo(dT)cellulose using calf thymus terminal transferase. After a wash with 75 ml of buffer A, terminal transferase activity was eluted with a linear gradient (200 ml) from 0 to 1.2 M potassium chloride in buffer A. Fractions containing terminal transferase activity were pooled and concentrated to yield fraction III.
Fraction III was diluted with 7 vol of 25 mM potassium phosphate, pH 7.2, containing 1 mM 2-mercaptoethanol, and applied to a column of hydroxylapatite (1.2 x 2.5 cm). After a wash with 50 ml of buffer A, terminal transferase activity was eluted with a linear gradient (200 ml) from 50 to 350 mM potassium phosphate, pH 7.2, containing 1 mM 2-mercaptoethanol. Fractions containing terminal transferase activity were pooled and concentrated to yield fraction IV. The purified protein which we obtained (0.11 mg) had a final specific activity of 55,180 U/mg, representing an overall yield of 67% (Table II) . Because of instability inherent in very diluted samples of terminal transferase, this specific activity represents a minimum estimated value. Stabilization of the enzyme activity by glycerol or exogenously added solutions of bovine serum albumin was ineffective.
Sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis. The subunit structure of homogeneous preparations of human terminal transferase was analyzed by denaturing gel electrophoresis in the presence of SDS. This procedure was conducted according to the methods of Laemmli (18) Osborn gel system, were immersed in a boiling water bath for 5 min. A set of protein standards (bovine serum albumin, relative mol wt (Mr) = 67,000; ovalbumin, Mr = 45,000; carbonic anhydrase, Mr = 30,000; and cytochrome c, M, = 11,500) were run simultaneously in separate gel tracks. In several instances, additional molecular weight markers were also employed (lactate dehydrogenase, Mr = 35,000; ct-chymotrypsinogen A, M, = 26,000; and lysozyme, M, = 14,300). Gels were stained by incubation for 12 h in a solution of 0.2% Coomassie Brilliant Blue R-250 in 50% methanol and 10% acetic acid, and destained in a solution containing 50% methanol and 10% acetic acid.
Isoelectricfocusing. The procedure for analytical slab gel isoelectric focusing of human terminal transferase has been (11, 21) . Antisera. Antisera were raised to terminal transferase purified from human leukemic cells and calf thymus (11, 12) . Rabbits were initially immunized with three injections, 50 ,ug each, of glutaraldehyde cross-linked terminal transferase using the schedule and conditions developed by Bollum (22 (4, 10, 22, 24, 25) . The second stage consisted of 15 ,Ml of 250 ug/ml fluorescein conjugated F(ab')2 goat antirabbit or rabbit anti-goat IgG. The percentage of fluorescent cells and the intracellular distribution of the fluorescence were determined using a fluorescence microscope with incident light excitation.
RESULTS
An analysis of the biochemical and biophysical properties of human terminal transferase required that the enzyme be purified to homogeneity from several different sources. Our criteria for homogeneity are: (a) the presence of a single polypeptide on SDS polyacrylamide gels or the presence of the previously reported twosubunit composition observed for the calf thymus enzyme (12) ; (b) a single band on nondenaturing isoelectric focusing gels (examples shown in Fig. 1); and (c) a specific activity that corresponds to protein preparations that were defined as homogeneous according to the criteria of nondenaturing polyacrylamide gel electrophoresis, SDS polyacrylamide gel electrophoresis, and analytical ultracentrifugation (12) . The enzymes were purified from acute leukemic lymphoblasts and from the blasts of patients with chronic myelogenous leukemia (CML) in blast crisis (11) . Terminal transferase isolated from greater than 100 g of starting material exhibited specific activities (-100,000 U/mg) comparable to the specific activity obtained for homogeneous calf thymus terminal transferase (12) . Our standard purification procedure, designed to %circumvent the low pH step and extended time required for purification (12) , was less successful for the isolation of terminal transferase from small quantities of tissue (<100 g). Thus, the specific activities of preparations 1 and 3 (Table III) represent lower limits of specific activity generally seen with homogeneous enzyme, due to the lack of stability inherent in very diluted samples of terminal transferase. To purify the enzyme from very small quantities of human thymus (<20 g), a shorter but highly successful purification method was devised (Table II) . When terminal transferase was puri- fied from 15 g of human thymus by the standard procedure using PMSF, only trace amounts ofprotein were available for characterization, while the modified procedure (Table II) yielded over 0.1 mg of purified protein. The enzymes with specific activities of <80,000
(preparations 1, 3, and 10) conformed to our other criteria for homogeneity. (27) .
At least three structural forms of terminal transferase have been found (Fig. 2) . Structural determinations were made over a 2-yr time span after each new enzyme purification. The gel preparations and procedures vary slightly and are detailed in the figure legend. The subunit structure of the purified enzyme from two patients with null cell ALL, and from MOLT-4 cells, is observed as a single polypeptide having a Mr = 62,000 as shown in Fig. 2a and b. In two additional enzyme preparations from untyped ALL, we found a single polypeptide species with aM, = 42,500 (Fig. 2c) .
Two types of subunit structure have been observed in enzyme from four patients with CML in blast crisis: (a) from two patients we isolated terminal transferase with a subunit mol wt of 42,500 (Fig. 2d) ; one of these patients' cells was not typed for surface markers, while the other formed fewer than 1% E rosettes; (b) from two patients we isolated terminal transferase with two nonidentical subunits of Mr = 27,000 and 10,000, (Fig. 2f  and g ). The cells ofone ofthese patients were T marked. Cells from the other patient were not typed. The denatured subunit structures of enzyme isolated from either calf thymus or human thymus were comparable to the structure of the enzyme from two patients with CML in blast crisis (Mr = 27,000 and 10,000, for human thymus, Fig. 2h ; and Mr = 30,500 and 9,500, for calf thymus, Fig. 2i ).
As one test for possible proteolysis, a potent inhibitor of a group of serine proteases, PMSF, was added during the initial stages of enzyme purification. The cells utilized for this purification were obtained from a patient with CML in blast crisis. Using the procedure in Table I we obtained a protein (M, = 42,500) that migrated as a single polypeptide on both denaturing polyacrylamide gels and on nondenaturing polyacrylamide isoelectric focusing gels. A protein with a mol wt of 62,000 was not observed. We do not know if all proteases that may be present in the extracts of this cell FIGURE 2 SDS-polyacrylamide gel electrophoresis of purified preparations of terminal transferase from the blasts of patients with ALL and CML in blast crisis, from normal human thymus, and from calf thymus. Preparations are listed in Table III . The electrophoresis of each sample is described in Methods. Sample concentrations varied from 5 to 15 Ag. Standards used for molecular weight standardization were: (1) bovine serum albumin (Mr = 67,000); (2) ovalbumin (Mr = 45,000); (3) carbonic anhydrase (M, = 30,000); (4) cytochrome c (M, = 11,550) . A description of each of the gels is as follows: (a) 6% stacking and 12% separating polyacrylamide gel according to the method of Laemmli (18) of terminal transferase purified from the blasts of a patient with ALL (preparation 2). (b) 10% running polyacrylamide gel according to the method of Weber and Osbom (19) of terminal transferase purified from the blasts of a patient with ALL (preparation 1). (c) 6% stacking and 12% separating polyacrylamide gel according to the method of Laemmli (18) of terminal transferase purified from the blast-infiltrated spleen ofa patient with ALL (Preparation 4). (d) 10% running polyacrylamide gel according to the method of Weber and Osbom (19) of terminal transferase purified from the blasts of a patient with CML'in blast crisis (preparation 6) . (e) 8% running polyacrylamide gel according to the method of Weber and Osbom (19) of terminal transferase purified from the blasts of a patient with ALL (preparation 5). (f) 6% stacking and 12% separating polyacrylamide gel according to the method of Laemmli (18) of terminal transferase purified from the blasts of a patient with CML in blast crisis (preparation 9). (g) 6% stacking and 12% separating polyacrylamide gel according to the method of Laemmli (18) ofterminal transferase purified from the blasts of a patient with CML in blast crisis (preparation 8). (h) 12% running polyacrylamide gel according to the method ofWeber apd Osbom (19) of terminal transferase purified from normal human thymus (preparation 10). (i) 6% stacking and 12% separating polyacrylamide gel according to the method ofLaemmli (18) ofterminal transferase purified from calfthymus (preparation 11).
preparation are inhibited by PMSF. We are therefore not able to rule out proteolysis by PMSF-insensitive proteases.
When data are summarized (Table III) , ALL blasts consistently have either the Mr = 62,000 or 42,500 sub-unit species. A Mr of 42,500 polypeptide or a Mr = 27,000 and 10,000 subunit pattern is associated with CML blasts. The low molecular weight enzyme with two nonidentical subunits (Mr = 27,000/ 10,000 in man) is observed in human and calf thymus. We have attempted to correlate molecular weight of terminal transferase protein with its intracellular localization by immunofluorescence techniques. Considering only the preparations listed in Table III , we find that the cells (non-T and non-B) from which the M, = 62,000 form of the enzyme was isolated (preparations 1, 2, and 3) give only nuclear immunofluorescence, whereas the cells from which the other forms of the enzyme are isolated show some cytoplasmic immunofluorescence (preparations 6-10). The correlation of the patterns of immunofluorescence with enzyme molecular structure is certainly intriguing, but will require considerably more examples before we can construct a statistical norm for each type ofcell. The similar kinetic properties of terminal transferases from thymus and leukemic blasts suggested that they could be derived from the same precursor molecule. It is also possible that terminal transferase occurs in multiple isozymic forms unrelated or distantly related in amino acid sequence. Direct evidence supporting close similarity in structure was obtained immunochemically. Precipitating and neutralizing antibodies to both calf and human terminal transferase were raised in rabbits.
Generally, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] ,ug of protein of either rabbit anti-calf terminal transferase or rabbit anti-human terminal transferase will give 50% inhibition of 1 U ofthe homologous terminal transferase. In the presence of excess antibody, inhibition of human and calf enzyme activity is >95%, when rabbit antibody to either antigen is used. Data for inhibition of each form of terminal transferase by rabbit anti-calf, rabbit anti-human, and goat antihuman terminal transferase are shown in Table IV . The titers ofantisera raised in goats were significantly lower than those obtained in rabbits, despite repeated booster immunizations. Only one of two immunized goats produced antiserum. Control sera from six unimmunized rabbits and two unimmunized goats substantially inhibited terminal transferase activity when mixed with tissue extracts containing the enzyme. This inhibition was eliminated by passing sera over Chelex-100 resin and then diluting it 1:3 with 5 mg/ml bovine serum albumin in phosphate-buffered saline. Although the inhibitor has not been identified, it is probably one or more metal ions. It is interesting to note that although rabbit antisera to the calf enzyme neutralize human terminal transferase slightly better than calf terminal transferase, rabbit antisera to the human enzyme neutralize human terminal transferase from four to seven times more effectively than calf terminal transferase. Goat antiserum to the human enzyme neutralizes all molecular forms of the human enzyme, whereas it has virtually no effect on the enzyme from calf thymus. Each type of human terminal transferase, regardless of polypeptide structure, is neutralized nearly identically by each type of antiserum. Thus, the human enzymes with Mr = 62,000, 42,500, and 27,000/10,000 show identical patterns of neutralization as shown in Fig. 3 . 1 U of each type of terminal transferase activity is inhibited by 5-7 itg of antiserum protein directed against the calf thymus enzyme in rabbits, by [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] ,ug antiserum protein directed against the human enzyme in rabbits and by Zg of antiserum protein directed against the human enzyme in goats.
Ouchterlony microdiffusion analyses of two types of antisera and four types of antigens are shown in Fig. 4 . Precipitating antibody is contained in each serum. Single precipitin lines without spurs are observed in reactions of antigenic identity when all forms of human terminal transferase are diffused against both types ofantisera. Spurs are observed when calf and human terminal transferase are compared so terminal transferases from the two species are immunochemically different (Fig. 4) .
Immunofluorescence studies were carried out using the sera directly, as well as specific antibody preparations that had been purified by chromatography on antigen affinity columns. Cells were obtained from human thymus. Most terminal transferase antigen was in the cytoplasm, as was also observed in rat thymocytes (9) . Satisfactory fluorescence was obtained with 0.60 ,ug of IgG per slide of affinity column purified rabbit anti- (a) a M, = 42,500 polypeptide subunit and (b) two nonidentical subunits of Mr = 27,000 and 10,000. Since not all of the CML patients had typing of cells, we are unable to ascribe a molecular weight structure to a particular type of CML blast. However, most patients with CML in blast crisis are typically null in type rather than T marked (29) . Therefore, one possible discrepancy in our hypothethical assignment of terminal transferase molecular structure to cell type is that we might have predicted that the enzyme isolated from CML blasts would be of the largest molecular weight, 62,000. Alternatively, it is possible that the state of dif-ferentiation of null cell ALL and blastic CML are not as similar as marker data suggest.
More direct assignment ofterminal transferase to cell type is hindered by our inability to isolate enough early normal progenitor cells ofdefined type (4, 30) for purification ofterminal transferase in sufficient quantities for structural investigations. However, there is evidence of phenotypic similarity between terminal transferase containing cells from normal marrow and lymphoblasts in common acute lymphoblastic leukemia (30) . Combined immunological assays for terminal transferase and membrane markers have shown that terminal transferase containing-cells in nonleukemic human bone marrow carry ALL-associated and Ia-like antigens, but no thymocyte markers or surface immunoglobulins. Normal terminal transferase containing cells in marrow could be the precursors involved in common non-B, non-T acute lymphoblastic leukemia. Under these circumstances the structure of terminal transferase may very well be identical in normal bone marrow lymphoid precursurs and blasts from null cell ALL.
Terminal transferases from thymus and lymphoblasts are catalytically and immunochemically similar. All of the molecular species are neutralized by the same antisera and give reactions of antigenic identity to one another when tested by immunodiffusion on Ouchterlony plates. They must be very similar in amino acid sequence. Although the biological function of terminal transferase is not known, it may act as a "somatic mutagen" to generate immunological diversity (5, 6) . Since this postulated mechanism of action requires activity during the processing of DNA, the active form of the enzyme is likely to be associated with the intranuclear species. By immunofluorescence studies, terminal transferase is located exclusively in the nucleus in marrow cells and in cells from ALL (10) . We have detected terminal transferase in blastic CML cells in both the nucleus and cytoplasm by immunofluorescence (27) . Goldschneider et al. (8) have reported a cytoplasmic location for terminal transferase protein in mouse thymocytes, and Janossy et al. (31) have demonstrated a predominantly nuclear location in human thymocytes. Isolation of the purified proteins that we report here demonstrate that regardless of the source or molecular weight, the protein is catalytically active and appears to be homogeneous in structure. Therefore, we cannot rule out the possibility that the cytoplasmic form of the enzyme plays an, as yet, undefined role in cellular metabolism.
The in vitro isolation of the different molecular forms of human terminal transferase we have described is not necessarily evidence for processing pathways in vivo. Increased levels of proteolytic enzymes in CML blasts and thymocytes relative to levels in ALL blasts offer an explanation for our observations. We have attempted to eliminate proteolysis as a problem during the purification of the enzyme from cells of one patient with CML in blast crisis, and from human thymus, by the addition of PMSF, and by the development of rapid purification schemes. In our experiments using PMSF and CML blast cells, we have found no evidence for the presence of a Mr = 62,000 form of the enzyme. We must conclude that a systematic investigation of the origin of multiple forms of terminal transferase should include an examination of physiological processing, artifactual degradation, or multiple isozymes coded by different genes for terminal transferase.
